Series  RIKB 38 0215Settlement Date  02/26/2025Total Amount Allocated (MM)  13,381All Bids Awarded At (Price / Yield)  98.464 / 6.680Total Number of Bids Received  63Total Amount of All Bids Received (MM)  17,431Total Number of Successful Bids  45Number of Bids Allocated in Full  45Lowest Price / Highest Yield Allocated  98.464 / 6.680Highest Price / Lowest Yield Allocated  99.565 / 6.550Lowest Price / Highest Yield Allocated in Full  98.464 / 6.680Weighted Average of Successful Bids (Price/Yield)  98.725 / 6.650Best Bid (Price / Yield)  99.565 / 6.550Worst Bid (Price / Yield)  97.545 / 6.790Weighted Average of All Bids Received (Price / Yield)  98.625 / 6.660Percentage Partial Allocation (Approximate)  100.00 %Bid to Cover Ratio  1.30

21 February – Fleet utilisation for January 2025 was 57 per cent.   Safe Notos and Safe Concordia operated at full capacity during this period, achieving 100% utilisation. Safe Eurus and Safe Zephyrus achieved a utilisation rate of 99% each. Safe Caledonia has commenced reactivation activities in Scapa Flow, UK, and will mobilise to the Captain Field, UK, within June 2025. Safe Boreas is in Norway preparing for relocation in Q2 2025 for a contract in Australia commencing between mid November 2025 and mid February 2026. Prosafe has entered into an agreement to sell Safe Concordia to an undisclosed party. The vessel is expected to be delivered to its new owner upon completion of her current charter obligations, within a window of March through June 2025. The sale of the vessel is subject to customary closing conditions and requirements. Safe...

Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025. Ester Baiget, President & CEO comments: “I want to thank Jacob for his strong leadership and commitment to Novonesis and our Food & Beverage Biosolutions business. Jacob has played an instrumental role in Novonesis. As a result of his contribution, the Food & Beverage Biosolutions business in Novonesis rests on a solid foundation with an extraordinary team and is uniquely positioned to drive continued growth and deliver innovative solutions to our customers. I wish Jacob all the best on his future journey.” Jacob joined Chr. Hansen in 2006 and became a member of the Corporate Leadership Team in 2013. During his tenure in Chr. Hansen,...

Havila Kystruten AS will publish its Q4 2024 financial report on Thursday, February 27, 2025. Bent Martini, CEO, and Aleksander Røynesdal, CFO, will present the results in an earnings call at 10:00 CET on Friday, February 28, 2025, followed by a Q&A session. The earnings call can be accessed through the following link: Link to the external registration page A recording will be available on the Company’s website. Contacts: Chief Executive Officer: Bent Martini, +47 905 99 650 Chief Financial Officer: Aleksander Røynesdal, +47 413 18 114

Physician caring for patientNurse caring for patientSystem ArchitectureFebruary 21, 2025 Integrating advanced data analytics into clinical practice to improve patient care Amsterdam, The Netherlands and Cambridge, MA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Mass General Brigham (MGB), home to one of the largest hospital system-based research enterprises in the US, today announced a new collaboration to develop and deploy advanced data infrastructure and AI designed to integrate and process live healthcare data from a wide range of sources to improve patient care. Today, healthcare providers often rely on disparate data sources, including static Electronic Medical Record (EMR) data, clinical notes, and isolated device alarms. By streaming accurate, reliable and detailed...

Put Option Agreements signed to date with 2025 OCEANEs holders representing 95.3% of the outstanding 2025 OCEANEs2025 OCEANEs holders’ general meeting convened for March 10, 2025Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 – GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the convening of the general meeting of the 2025 OCEANEs holders for March 10, 2025. Preliminary results of the Repurchase As announced on February 10, 2025 and February 14, 2025, GENFIT has proposed to all of the 2025 OCEANEs holders to enter into a Put Option Agreement, pursuant to which GENFIT will unconditionally...

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025 Event to Feature Renowned Gastroenterologist Dr. David Rubin, Highlighting the Ulcerative Colitis Treatment Landscape and Abivax’s Pivotal ABTECT Phase 3 Trial PARIS, France – February 21, 2025 – 8:30 AM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for chronic inflammatory diseases, today announced it will host a Key Opinion Leader (KOL) Investor Webcast on Monday, March 17, 2025, at 9:00 a.m. EDT (2:00 p.m. CET). The webcast will feature Professor David T. Rubin, MD, Chief of the Section of Gastroenterology, Hepatology, and Nutrition and Director of the Inflammatory Bowel Disease Center at The University of Chicago. Dr. Rubin will provide...